Kura Oncology (KURA)

$8.77 +0.12 (1.33%)
Market Cap 768.34M
Revenue (ttm) 67.48M
Net Income (ttm) -278.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -412.97%
Debt to Equity Ratio 0.09
Volume 2,094,000
Avg Vol 1,655,214
Day's Range N/A - N/A
Shares Out 88.77M
Stochastic %K 5%
Beta 0.36
Analysts Strong Sell
Price Target $30.83

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabe...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 500 8800
Address:
4930 Directors Place, Suite 500, San Diego, United States
Adriana88
Adriana88 Jun. 4 at 11:33 PM
$KURA Weak revenue base vs cost structure..,,
0 · Reply
jeffrman777
jeffrman777 Jun. 4 at 5:41 PM
$KURA $SNDX Have y’all considered the possibility that it’s not really a contest between the two and both are shit 🤣 jk
3 · Reply
lowfloatscambuster
lowfloatscambuster Jun. 4 at 5:11 PM
$KURA just insane. $SNDX not getting bought given their $250M raise provides a clear read-through that Zifto is legit. EV Of $100-$200M. Just crazy.
0 · Reply
Quantumup
Quantumup Jun. 4 at 12:03 PM
Citizens on $KURA: We reiterate our Market Outperform rating on Kura Oncology and price target of $24, based on a blended discounted EPS and revenue multiple analysis. $BMY SNDX AMGN ABBV - RHHBY $RVMD Here's what Citizens additionally said: https://x.com/Quantumup1/status/2062504701707370657?s=20
0 · Reply
jeffrman777
jeffrman777 Jun. 4 at 2:33 AM
$KURA $SNDX $XBI ASCO selloff has been tragic.
1 · Reply
Nabepe
Nabepe Jun. 3 at 8:26 PM
$KURA Any upgrade.of the conference?
0 · Reply
Stockseeking
Stockseeking Jun. 3 at 2:52 PM
$KURA Bought more, 2025 Q1 2.1m; 2026 Q2 5.8m; and up from here
0 · Reply
Orlandotrader
Orlandotrader Jun. 3 at 2:28 PM
$KURA Acts terrible. Going back to 8$.
0 · Reply
JFais
JFais Jun. 3 at 1:44 PM
$KURA (L) Preclinical studies showed enhanced anti-tumor activity across multiple classes of RAS inhibitors (mutant & multi-selective RAS(ON) + pan-KRAS & pan-RAS) Will start combo study with $RVMD dara in PDAC Foundational backbone for molecularly defined cancers $100M EV
0 · Reply
quickaspeter
quickaspeter Jun. 3 at 12:38 PM
$KURA Let’s get going…💥🚀💰💰💰
0 · Reply
Latest News on KURA
Kura Oncology Transcript: Investor update

Jun 3, 2026, 3:15 PM EDT - 1 day ago

Kura Oncology Transcript: Investor update

Kura Oncology Press release: Investor update

Jun 3, 2026, 3:15 PM EDT - 1 day ago

Kura Oncology Press release: Investor update

Kura Oncology Slides: Investor update

Jun 3, 2026, 3:15 PM EDT - 1 day ago

Kura Oncology Slides: Investor update

Kura reports data supporting darlifarnib potential for KRAS-mutant cancers

2026-06-03T11:45:26.000Z - 1 day ago

Kura reports data supporting darlifarnib potential for KRAS-mutant cancers

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Jun 3, 2026, 6:53 AM EDT - 1 day ago

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Jun 2, 2026, 8:32 AM EDT - 2 days ago

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 1:30 PM EDT - 9 days ago

Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Kura Oncology Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 9 days ago

Kura Oncology Proxy statement: Proxy filing

Kura Oncology reports first-in-human data from the FIT-001 clinical trial

2026-05-26T10:22:44.000Z - 9 days ago

Kura Oncology reports first-in-human data from the FIT-001 clinical trial

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

May 26, 2026, 6:02 AM EDT - 9 days ago

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

May 19, 2026, 4:02 PM EDT - 16 days ago

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 6:00 PM EDT - 22 days ago

Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026

Kura Oncology reports Q1 EPS (83c), consensus (78c)

2026-05-12T21:25:48.000Z - 23 days ago

Kura Oncology reports Q1 EPS (83c), consensus (78c)

Kura Oncology Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 23 days ago

Kura Oncology Earnings Call Transcript: Q1 2026

Kura Oncology Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 23 days ago

Kura Oncology Earnings release: Q1 2026

Kura Oncology Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 23 days ago

Kura Oncology Quarterly report: Q1 2026

Kura Oncology Reports First Quarter 2026 Financial Results

May 12, 2026, 4:02 PM EDT - 23 days ago

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology Slides: Corporate presentation

May 12, 2026, 4:00 PM EDT - 23 days ago

Kura Oncology Slides: Corporate presentation

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

2026-05-12T19:13:17.000Z - 23 days ago

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

May 12, 2026, 9:40 AM EDT - 23 days ago

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 6, 2026, 7:30 AM EDT - 4 weeks ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

May 5, 2026, 7:30 AM EDT - 4 weeks ago

Kura Oncology to Report First Quarter 2026 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 7:30 AM EDT - 4 weeks ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology Transcript: Investor Update

Apr 17, 2026, 10:30 AM EDT - 6 weeks ago

Kura Oncology Transcript: Investor Update

Kura Oncology Press release: Investor Update

Apr 17, 2026, 10:30 AM EDT - 6 weeks ago

Kura Oncology Press release: Investor Update

Kura Oncology Slides: Investor Update

Apr 17, 2026, 10:30 AM EDT - 6 weeks ago

Kura Oncology Slides: Investor Update

Kura Oncology reports results from ongoing FIT-001 clinical trial

2026-04-17T10:06:05.000Z - 6 weeks ago

Kura Oncology reports results from ongoing FIT-001 clinical trial

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Apr 17, 2026, 6:00 AM EDT - 6 weeks ago

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology initiated with a Buy at Lake Street

2026-04-14T11:42:35.000Z - 7 weeks ago

Kura Oncology initiated with a Buy at Lake Street

Kura Oncology Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 7 weeks ago

Kura Oncology Proxy statement: Proxy filing

Kura Oncology Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 7 weeks ago

Kura Oncology Proxy statement: Proxy filing

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Apr 9, 2026, 7:30 AM EDT - 2 months ago

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Syndax assumed with a Buy at Jefferies

2026-03-30T13:08:09.000Z - 2 months ago

Syndax assumed with a Buy at Jefferies

SNDX

Kura Oncology price target lowered to $25 from $30 at Mizuho

2026-03-24T15:07:11.000Z - 2 months ago

Kura Oncology price target lowered to $25 from $30 at Mizuho

Kura Oncology price target lowered to $15 from $16 at UBS

2026-03-13T13:43:20.000Z - 2 months ago

Kura Oncology price target lowered to $15 from $16 at UBS

Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 9:00 AM EDT - 3 months ago

Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference

Kura Oncology Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 3 months ago

Kura Oncology Transcript: Leerink Global Healthcare Conference 2026

Kura Oncology price target raised to $30 from $29 at BofA

2026-03-06T14:25:12.000Z - 3 months ago

Kura Oncology price target raised to $30 from $29 at BofA

Kura Oncology price target lowered to $36 from $38 at Wedbush

2026-03-06T12:48:51.000Z - 3 months ago

Kura Oncology price target lowered to $36 from $38 at Wedbush

Kura Oncology Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Kura Oncology Earnings Call Transcript: Q4 2025

Kura Oncology Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Kura Oncology Annual report: Q4 2025

Kura Oncology Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Kura Oncology Earnings release: Q4 2025

Kura Oncology Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 3 months ago

Kura Oncology Slides: Corporate presentation

Kura Oncology reports Q4 EPS (92c), consensus (49c)

2026-03-05T11:36:05.000Z - 3 months ago

Kura Oncology reports Q4 EPS (92c), consensus (49c)

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 6:31 AM EST - 3 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Kura Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 11:50 AM EST - 3 months ago

Kura Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Kura Oncology management to meet with Citizens

2026-03-03T18:35:52.000Z - 3 months ago

Kura Oncology management to meet with Citizens

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:30 AM EST - 3 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Kura Oncology to Participate in Three Upcoming Investor Conferences

Feb 25, 2026, 7:30 AM EST - 3 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology price target lowered to $29 from $30 at BofA

2026-02-03T11:50:13.000Z - 4 months ago

Kura Oncology price target lowered to $29 from $30 at BofA

Kura Oncology price target lowered to $20 from $25 at Leerink

2026-01-13T14:16:07.000Z - 5 months ago

Kura Oncology price target lowered to $20 from $25 at Leerink

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Jan 11, 2026, 5:00 PM EST - 5 months ago

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Kura Oncology Transcript: Status Update

Dec 8, 2025, 12:30 PM EST - 6 months ago

Kura Oncology Transcript: Status Update

Kura Oncology Press release: Status Update

Dec 8, 2025, 12:30 PM EST - 6 months ago

Kura Oncology Press release: Status Update

Kura Oncology Slides: Status Update

Dec 8, 2025, 12:30 PM EST - 6 months ago

Kura Oncology Slides: Status Update

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Dec 8, 2025, 10:30 AM EST - 6 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 3, 2025, 8:32 AM EST - 6 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Dec 2, 2025, 8:02 AM EST - 6 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Nov 25, 2025, 5:16 PM EST - 6 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Kura Oncology Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 10:30 AM EST - 7 months ago

Kura Oncology Transcript: Jefferies London Healthcare Conference 2025

Kura Oncology Transcript: FDA Announcement

Nov 13, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Transcript: FDA Announcement

Kura Oncology Press release: FDA Announcement

Nov 13, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Press release: FDA Announcement

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:51 AM EST - 7 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

US FDA approves Kura Oncology's blood cancer therapy

Nov 13, 2025, 10:32 AM EST - 7 months ago

US FDA approves Kura Oncology's blood cancer therapy

Kura Oncology to Participate in Upcoming Investor Conference

Nov 12, 2025, 4:05 PM EST - 7 months ago

Kura Oncology to Participate in Upcoming Investor Conference

Kura Oncology Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Kura Oncology Earnings Call Transcript: Q3 2025

Kura Oncology Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Kura Oncology Quarterly report: Q3 2025

Kura Oncology Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Kura Oncology Earnings release: Q3 2025

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 6:31 AM EST - 7 months ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Nov 3, 2025, 4:02 PM EST - 7 months ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Nov 3, 2025, 9:14 AM EST - 7 months ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 7 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 24, 2025, 7:02 AM EDT - 7 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Kura Oncology Transcript: ESMO Congress 2025

Oct 18, 2025, 1:30 PM EDT - 8 months ago

Kura Oncology Transcript: ESMO Congress 2025

Kura Oncology Slides: FY 2025

Oct 18, 2025, 1:30 PM EDT - 8 months ago

Kura Oncology Slides: FY 2025

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 18, 2025, 3:23 AM EDT - 8 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Kura Oncology Transcript: UBS Virtual Oncology Day

Oct 1, 2025, 2:30 PM EDT - 8 months ago

Kura Oncology Transcript: UBS Virtual Oncology Day

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Oct 1, 2025, 7:01 AM EDT - 8 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 8 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 25, 2025, 5:18 PM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Kura Oncology Transcript: Study Update

Sep 16, 2025, 4:30 PM EDT - 9 months ago

Kura Oncology Transcript: Study Update

Kura Oncology Press release: Study Update

Sep 16, 2025, 4:30 PM EDT - 9 months ago

Kura Oncology Press release: Study Update

Kura Oncology Slides: Study Update

Sep 16, 2025, 4:30 PM EDT - 9 months ago

Kura Oncology Slides: Study Update

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 16, 2025, 4:01 PM EDT - 9 months ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Kura Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 1:50 PM EDT - 9 months ago

Kura Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Kura Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 1:00 PM EDT - 9 months ago

Kura Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Kura Oncology Slides: Corporate Presentation

Sep 7, 2025, 6:00 PM EDT - 9 months ago

Kura Oncology Slides: Corporate Presentation

Kura Oncology Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:35 AM EDT - 9 months ago

Kura Oncology Transcript: Cantor Global Healthcare Conference 2025

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Sep 3, 2025, 8:02 AM EDT - 9 months ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Earnings Call Transcript: Q2 2025

Kura Oncology Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Quarterly report: Q2 2025

Kura Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Earnings release: Q2 2025

Kura Oncology Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Kura Oncology Transcript: Status Update

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Transcript: Status Update

Kura Oncology Slides: Status Update

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Slides: Status Update

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Kura Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 11:20 AM EDT - 1 year ago

Kura Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Kura Oncology Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Kura Oncology Transcript: Jefferies Global Healthcare Conference 2025

Kura Oncology Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2025

Jun 2, 2025, 7:30 PM EDT - 1 year ago

Kura Oncology Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2025

Kura Oncology Slides: FY 2025

Jun 2, 2025, 7:30 PM EDT - 1 year ago

Kura Oncology Slides: FY 2025

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Jun 2, 2025, 6:00 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Jun 1, 2025, 7:00 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 9:00 AM EDT - 1 year ago

Kura Oncology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 22, 2025, 5:30 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 10:00 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Kura Oncology Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 6:00 PM EDT - 1 year ago

Kura Oncology Transcript: BofA Securities 2025 Healthcare Conference

Kura Oncology Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Earnings Call Transcript: Q1 2025

Kura Oncology Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Quarterly report: Q1 2025

Kura Oncology Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Earnings release: Q1 2025

Kura Oncology Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 1 year ago

Kura Oncology Reports First Quarter 2025 Financial Results

Kura Oncology Slides: Corporate Presentation

May 1, 2025, 7:00 AM EDT - 1 year ago

Kura Oncology Slides: Corporate Presentation

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology to Report First Quarter 2025 Financial Results

Kura Oncology Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Proxy statement: Proxy Filing

Kura Oncology Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Proxy statement: Proxy Filing

Kura Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 8, 2025, 10:30 AM EDT - 1 year ago

Kura Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Kura Oncology Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Transcript: Leerink Global Healthcare Conference 2025

Kura Oncology Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 9:30 AM EDT - 1 year ago

Kura Oncology Transcript: Barclays 27th Annual Global Healthcare Conference

Kura Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 2:30 PM EST - 1 year ago

Kura Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Kura Oncology Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Earnings Call Transcript: Q4 2024

Kura Oncology Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Annual report: Q4 2024

Kura Oncology Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Earnings release: Q4 2024

Kura Oncology Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Slides: Q4 2024

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:03 PM EST - 1 year ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 1 year ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology Transcript: Study Update

Feb 5, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Transcript: Study Update

Kura Oncology Press release: Study Update

Feb 5, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Press release: Study Update

Kura Oncology Slides: Study Update

Feb 5, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Slides: Study Update

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Feb 5, 2025, 4:01 PM EST - 1 year ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Adriana88
Adriana88 Jun. 4 at 11:33 PM
$KURA Weak revenue base vs cost structure..,,
0 · Reply
jeffrman777
jeffrman777 Jun. 4 at 5:41 PM
$KURA $SNDX Have y’all considered the possibility that it’s not really a contest between the two and both are shit 🤣 jk
3 · Reply
lowfloatscambuster
lowfloatscambuster Jun. 4 at 5:11 PM
$KURA just insane. $SNDX not getting bought given their $250M raise provides a clear read-through that Zifto is legit. EV Of $100-$200M. Just crazy.
0 · Reply
Quantumup
Quantumup Jun. 4 at 12:03 PM
Citizens on $KURA: We reiterate our Market Outperform rating on Kura Oncology and price target of $24, based on a blended discounted EPS and revenue multiple analysis. $BMY SNDX AMGN ABBV - RHHBY $RVMD Here's what Citizens additionally said: https://x.com/Quantumup1/status/2062504701707370657?s=20
0 · Reply
jeffrman777
jeffrman777 Jun. 4 at 2:33 AM
$KURA $SNDX $XBI ASCO selloff has been tragic.
1 · Reply
Nabepe
Nabepe Jun. 3 at 8:26 PM
$KURA Any upgrade.of the conference?
0 · Reply
Stockseeking
Stockseeking Jun. 3 at 2:52 PM
$KURA Bought more, 2025 Q1 2.1m; 2026 Q2 5.8m; and up from here
0 · Reply
Orlandotrader
Orlandotrader Jun. 3 at 2:28 PM
$KURA Acts terrible. Going back to 8$.
0 · Reply
JFais
JFais Jun. 3 at 1:44 PM
$KURA (L) Preclinical studies showed enhanced anti-tumor activity across multiple classes of RAS inhibitors (mutant & multi-selective RAS(ON) + pan-KRAS & pan-RAS) Will start combo study with $RVMD dara in PDAC Foundational backbone for molecularly defined cancers $100M EV
0 · Reply
quickaspeter
quickaspeter Jun. 3 at 12:38 PM
$KURA Let’s get going…💥🚀💰💰💰
0 · Reply
Nabepe
Nabepe Jun. 3 at 11:44 AM
$KURA I hope they make a better deal with Darlifarnib and can have a better profit margin.
0 · Reply
septrading
septrading Jun. 3 at 11:02 AM
$KURA https://www.globenewswire.com/news-release/2026/06/03/3305888/35186/en/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy.html
0 · Reply
Rubener
Rubener Jun. 2 at 4:13 PM
$KURA
0 · Reply
CapitalMonk
CapitalMonk Jun. 2 at 3:23 PM
$KURA Price: $9.12 (+0.94%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±3.39% RSI: 45.5 | Momentum: Moderate Volume: -61.8% vs avg Volatility: 5.46% Support: $8.69 | Resistance: $11.52 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
AdiDasRom
AdiDasRom Jun. 2 at 1:53 PM
$KURA "Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML" YF
0 · Reply
Olena
Olena Jun. 1 at 8:18 PM
$KURA did someone die today????
1 · Reply
Arcides
Arcides Jun. 1 at 3:13 PM
$KURA bios are pathetic...
1 · Reply
Nabepe
Nabepe Jun. 1 at 3:07 PM
$IDYA $SPRO $VERA $KURA bad day across the whole sector
1 · Reply
Windee
Windee Jun. 1 at 2:59 PM
$KURA 👀👀Could it be $KURA got mixed up with $KRUS? Only good news on $KURA JUMPED in here. Let’s see.
1 · Reply
jeffrman777
jeffrman777 Jun. 1 at 2:44 PM
$KURA $SNDX $XBI Shit day across the sector. Just gotta hang in there.
1 · Reply
Rubener
Rubener Jun. 1 at 1:58 PM
$KURA no surprise here
0 · Reply
AdiDasRom
AdiDasRom May. 31 at 7:23 PM
$KURA From what I've seen, only good news on nuvb, kura, sndx and iova. Organic increases and decreases are coming until the acquisitions come sooner or later. Good luck to everyone!
0 · Reply